NEW YORK, Feb 21 - Zygogen of Atlanta will provide Curis with its
proprietary transgenic zebrafish technology for use in genomics-based drug
discovery, Zygogen said Wednesday.

Zebrafish are similar to knockout mice in that they can serve as model
organisms for finding genome-based drug targets, but they offer the
advantage of being faster to breed and less expensive.

Zygogen, founded in 1999, uses Z-Tag, a technology through which it can
design transgenic zebrafish with organs that are labeled and cell lineages

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.